Nexium with new dose for pediatric patients...

AstraZeneca, makers of Nexium, announced that Nexium is now indicated for use in pediatric patients aged from 1 year to 17 years for the treatment of reflux esophagitis and nonerosive reflux disease. Based on the new dose, this company launching a new 10 mg sachet formulation for pediatric patients aged between 1 and 11 years to be taken orally as a drink or via naso-gastric tube.
The new dose ‘reflux esophagitis’ in children aged between 1 and 11 years is based on the weight. If the weight is less than 20 kg, the dose would be 10 mg sachet once daily for 3 weeks, or if weight is more than 20 kg, then dose would be 20 mg (2 sachets of 10 mg) once daily for 8 weeks. The dose for children aged between 12 and 17 years would be 20 mg to 40 mg once daily for 4 to 8 weeks. Safety study is not done beyond 8 weeks.